Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?
Tóm tắt
Hypocalcemia was reported at low rates (0.05–1.7%) in denosumab-treated postmenopausal women with osteoporosis. This real-life study shows a 7.4% rate of denosumab-induced hypocalcemia in community-dwelling osteoporotic men and women. Pretreatment serum calcium and creatinine levels are major predictors for this complication. Serum-calcium monitoring may help to identify and prevent severe hypocalcemia. RCTs have reported a 0.05–1.7% rate of hypocalcemia in denosumab-treated postmenopausal women with osteoporosis, but long-term real-life data are lacking. We assessed the rate of hypocalcemia in osteoporotic community-dwelling patients treated with denosumab. A retrospective analysis was conducted based on medical records (2010–2018) from a large HMO. An albumin-adjusted serum calcium concentration lower than 8.5 mg/dL was defined as hypocalcemia. We included 2005 patients (93% women, mean age 76 ± 9 years). Hypocalcemia developed during treatment in 149 patients (7.4%; 1% less than 8 mg/dL): in 66 after 0.5–1 years; 48 after 1–2 years; 35 after > 2 years. On comparison of the hypocalcemic and normocalcemic patients, the strongest predictors of hypocalcemia were pretreatment levels of albumin-adjusted serum calcium (9.1 ± 0.4 vs. 9.4 ± 0.5 mg/dL, respectively; p < 0.05) and creatinine (0.9 ± 0.5 vs. 0.8 ± 0.3 mg/dL, respectively; p < 0.05). The hypocalcemia rate increased in parallel to a decrease in eGFR (p = 0.032 for the difference between eGFR ranges). Baseline calcium level ≤ 9.31 mg/dL predicted hypocalcemia with a sensitivity of 77% and specificity of 56%. A model of (− 2)*calcium + creatinine predicted hypocalcemia (3.7% when lower and 17.1% when higher than − 17.4). Gender, age, 25-hydroxyvitamin-D, parathyroid hormone, alkaline phosphatase, and whether denosumab was given as first or advanced line of osteoporotic therapy had no predictive value. Real-life rates of denosumab-induced hypocalcemia are higher than previously reported. Hypocalcemia might develop after each dose of denosumab in ongoing treatment. Adequate calcium and vitamin D supplementation are needed. Serum calcium monitoring is advised in high-risk patients for early detection of severe hypocalcemia.
Tài liệu tham khảo
Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) FREEDOM trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765. https://doi.org/10.1056/NEJMoa0809493
Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677–692. https://doi.org/10.1016/j.bone.2010.11.020
Drugs@FDA: FDA approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=125320. Accessed September 23, 2018
Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479. https://doi.org/10.1002/jbmr.1613
Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26:1829–1835. https://doi.org/10.1002/jbmr.403
Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 51:1812–1821. https://doi.org/10.1016/j.ejca.2015.05.016
Bridgeman MB, Pathak R (2011) Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin Ther 33:1547–1559. https://doi.org/10.1016/j.clinthera.2011.10.008
Dave V, Chiang CY, Booth J, Mount PF (2015) Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Am J Nephrol 41:129–137. https://doi.org/10.1159/000380960
Chen J, Smerdely P (2017) Hypocalcaemia after denosumab in older people following fracture. Osteoporos Int 28:517–522. https://doi.org/10.1007/s00198-016-3755-8
Huynh ALH, Baker ST, Stewardson AJ, Johnson DF (2016) Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf 25:1274–1278. https://doi.org/10.1002/pds.4045
Ishikawa K, Nagai T, Sakamoto K, Eguro T, Ito H, Toyoshima Y, Kokaze A, Toyone T, Inagaki K (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag 12:1831–1840. https://doi.org/10.2147/TCRM.S123172
Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, Minakuchi K (2013) Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 36:1622–1626
Asano T, Shimizu T, Takahashi D, Ota M, Sato D, Hamano H, Hiratsuka S, Takahata M, Iwasaki N (2019) Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol. J Bone Miner Metab 37:351–357. https://doi.org/10.1007/s00774-018-0928-x
Toulis K, Iliadou P, Mandanas S, Kazila P, Margaritidou E, Georgopoulos K, Pazaitou-Panayiotou K (2016) Calcium homeostasis in women with non-metastatic breast cancer with osteoporosis after a single dose of denosumab: a pilot study. Hormones 15:560–562. https://doi.org/10.14310/horm.2002.1693
Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M (2019) Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int 30:241–249. https://doi.org/10.1007/s00198-018-4688-1
Nakamura Y, Suzuki T, Kamimura M, Murakami K, Ikegami S, Uchiyama S, Kato H (2017) Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res 5:17021. https://doi.org/10.1038/boneres.2017.21
Clalit Health Services. https://www.btl.gov.il/Publications/survey/Documents/seker_271.pdf
Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther 30:239–245. https://doi.org/10.1038/clpt.1981.154
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F (2006) Chronic kidney disease epidemiology collaboration. Using standardized serum creatinine values in the modificatin of diet in renal disease study equation for estimating glomerual filtration rate. Ann Intern Med 145:247–254. https://doi.org/10.7326/0003-4819-145-4-200608150-00004
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomized FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523. https://doi.org/10.1016/S2213-8587(17)30138-9
Prolia (denosumab) package insert. https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/prolia/prolia_pi.pdf
Bekker PJ, Holloway DL, Rasmussen AS, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066. https://doi.org/10.1359/JBMR.040305
Chen F, Pu F (2016) Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat 39:453–459. https://doi.org/10.1159/000447372
Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139. https://doi.org/10.1200/JCO.2010.29.7101
Lechner B, DeAngelis C, Jamal N, Emmenegger U, Pulenzas N, Giotis A, Sheehan P, Tsao M, Bedard G, Chow E (2014) The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Support Care Cancer 22:1765–1771. https://doi.org/10.1007/s00520-014-2142-2
Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, Sharma K, Wijarnpreecha K, Ungprasert P, Gonzalez Suarez ML, Cheungpasitporn W (2018) Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int 29:1737–1745. https://doi.org/10.1007/s00198-018-4533-6
Pharmaceuticals and Medical Devices Agency. Dear Healthcare Professional Letter of Rapid Safety Communication, RANMARK. https://www.pmda.go.jp/files/000153380.pdf
Takeyama M, Sai K, Imatoh T, Segawa K, Hirasawa N, Saito Y (2017) Influence of Japanese regulatory action on denosumab-related hypocalcemia using Japanese adverse drug event report database. Biol Pharm Bull 40:1447–1453. https://doi.org/10.1248/bpb.b17-00266
Talreja DB (2012) Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assess 1:30–33. https://doi.org/10.3109/21556660.2012.668504
McCormick BB, Davis J, Burns KD (2012) Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 60:626–628. https://doi.org/10.1053/j.ajkd.2012.06.019
Monge Rafael P, Arias M, Fernández-Fresnedo G (2016) Hipocalcemia severa tras la administración de una dosis de denosumab en un paciente con insuficiencia renal avanzada. Nefrología 36:446–448. https://doi.org/10.1016/j.nefro.2016.02.007
Takami H, Washio K, Gotoh H (2017) Denosumab for male hemodialysis patients with low bone mineral density: a case-control study. Int J Nephrol 2017:1–5. https://doi.org/10.1155/2017/6218129
Monge Rafael P, Martin de Francisco ÁL, Fernández-Fresnedo G (2018) Denosumab y enfermedad renal crónica avanzada: hipocalcemia severa con riesgo vital. Nefrología 38:97–98. https://doi.org/10.1016/j.nefro.2017.01.004
Hiramatsu R, Ubara Y, Sawa N, Hoshino J, Hasegawa E, Kawada M, Imafuku A, Sumida K, Mise K, Hayami N, Suwabe T, Takaichi K (2015) Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial. Am J Kidney Dis 66:175–177. https://doi.org/10.1053/j.ajkd.2015.03.012
Festuccia F, Jafari MT, Moioli A, Fofi C, Barberi S, Amendola S, Sciacchitano S, Punzo G, Menè P (2017) Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 30:271–279. https://doi.org/10.1007/s40620-016-0334-1
Cernes R, Barnea Z, Biro A, Zandman-Goddard G, Katzir Z (2017) Severe hypocalcemia following a single denosumab injection. Isr Med Assoc J 19:719–721
Farinola N, Kanjanapan Y (2013) Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Intern Med J 43:1243–1246. https://doi.org/10.1111/imj.12283
Chen CL, Chen NC, Hsu CY, Chou KJ, Lee PT, Fang HC, Renn JH (2014) An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99:2426–2432. https://doi.org/10.1210/jc.2014-1154
Martín-Baez IM, Blanco-García R, Alonso-Suárez M, Cossio-Aranibar C, Beato-Coo LV, Fernández-Fleming F (2013) Severe hypocalcaemia post-denosumab. Nefrologia 33:614–615. https://doi.org/10.3265/Nefrologia.pre2013.Apr.11922
Ishikawa K, Nagai T, Tsuchiya K, Oshita Y, Kuroda T, Ito H, Tani S, Dodo Y, Toyone T, Inagaki K (2018) High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis. Clin Interv Aging 13:1929–1934. https://doi.org/10.2147/CIA.S180614
Kostenuik PJ, Smith SY, Samadfam R, Jolette J, Zhou L, Ominsky MS (2015) Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys. J Bone Miner Res 30:657–669. https://doi.org/10.1002/jbmr.2401
Body J-J, Niepel D, Tonini G (2017) Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer 25:1639–1649. https://doi.org/10.1007/s00520-016-3543-1
Makras P, Polyzos SA, Papatheodorou A, Kokkoris P, Chatzifotiadis D, Anastasilakis AD (2013) Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol 79:499–503. https://doi.org/10.1111/cen.12188